As reduced serum AREG levels correlated with longer progression-free survival of non-small-cell lung cancer patients treated with SBRT and immune checkpoint blockade, the potential of systemic AREG inhibition to delay tumor progression was evaluated [219]. This evidence concerns the gene AREG and non-small cell lung carcinoma.